QuidelOrtho To Participate In Upcoming Investor Conferences
Get Alerts QDEL Hot Sheet
Join SI Premium – FREE
- Evercore ISI 8th Annual Healthcare Conference,
Tuesday, December 2, 2025
Members of QuidelOrtho's management team are scheduled to participate in a fireside chat at10:00 a.m. ET /7:00 a.m. PT . - Citi Global Healthcare Conference,
Wednesday, December 3, 2025
Members of QuidelOrtho's management team are scheduled to participate in a fireside chat at1:00 p.m. ET /10:00 a.m. PT .
Interested parties can access the live webcast and replay in the "Events & Presentations" section of the "Investor Relations" page of QuidelOrtho's website at https://ir.quidelortho.com/.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
With expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing, QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of diagnostic solutions, delivering fast, accurate and reliable results that help improve patient outcomes – from the point of care to hospital, lab to clinic. Building on a legacy of innovation, QuidelOrtho works with healthcare providers to advance diagnostics that connect insights with solutions, defining a clearer path for informed decisions and better care.
Investor Contact:
Vice President, Investor Relations
[email protected]
Media Contact:
Senior Director, Corporate Communications
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/quidelortho-to-participate-in-upcoming-investor-conferences-302624120.html
SOURCE QuidelOrtho Corporation
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Monster Energy and Call of Duty® Take Over Cosm Los Angeles for Immersive Modern Warfare® 4 Launch Celebration
- Best Protective iPhone Cases for 2026: Top Slim and Drop-Protection Options for iPhone 18 Pro & iPhone 18 Pro Max Recommended by Consumer365
- New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share